1008764-20-2

Basic information

• Product Name: 4-[3-(2-cyclohexylethoxy)benzoyl]-N-(5-hydroxypyridin-3-yl)piperazine-1-carboxamide
• Synonyms: 4-[3-(2-cyclohexylethoxy)benzoyl]-N-(5-hydroxypyridin-3-yl)piperazine-1-carboxamide
• CAS NO: 1008764-20-2
• Molecular Weight: 452.553
• Mol File: 1008764-20-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-[3-(2-cyclohexylethoxy)benzoyl]-N-(5-hydroxypyridin-3-yl)piperazine-1-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[3-(2-cyclohexylethoxy)benzoyl]-N-(5-hydroxypyridin-3-yl)piperazine-1-carboxamide(1008764-20-2)
• EPA Substance Registry System: 4-[3-(2-cyclohexylethoxy)benzoyl]-N-(5-hydroxypyridin-3-yl)piperazine-1-carboxamide(1008764-20-2)

Safety Data

• Hazardous Substances Data: 1008764-20-2(Hazardous Substances Data)

Upstream product

• 30766-22-4 methyl 5-hydroxy-3-pyridinecarboxylate 
• 1008775-33-4 sodium 5-benzyloxynicotinate 
• 1008775-34-5 5-(benzyloxy)nicotinoylazide 
• 219817-42-2 methyl 5-(benzyloxy)nicotinate 
• 1008775-35-6 N-[5-(benzyloxy)pyridin-3-yl]-4-[3-(2-cyclohexylethoxy)benzoyl]piperazine-1-carboxamide 

Downstream Products

• 1008775-36-7 N-{5-[2-(benzyloxy)ethoxy]pyridin-3-yl}-4-[3-(2-cyclohexylethoxy)benzoyl]piperazine-1-carboxamide 
• 1008764-31-5 ({5-[({4-[3-(2-cyclohexylethoxy)benzoyl]piperazin-1-yl}carbonyl)amino]pyridin-3-yl}oxy)acetic acid 
• 1008764-22-4 4-[3-(2-cyclohexylethoxy)benzoyl]-N-[5-(2-hydroxyethoxy)pyridin-3-yl]piperazine-1-carboxamide 
• 1008775-37-8 ethyl ({5-[({4-[3-(2-cyclohexylethoxy)benzoyl]piperazin-1-yl}carbonyl)amino]pyridin-3-yl}oxy)acetate 

Relevant articles and documents

UREA COMPOUND OR SALT THEREOF

[Object] To provide a compound which can be used for the treatment of a disease associated with fatty acid amide hydrolase (FAAH), particularly urinary frequency, urinary incontinence and/or overactive bladder. [Means for solution] It is confirmed that a urea compound chemical-structurally characterized by having a piperidine or piperazine ring or a salt thereof has an excellent FAAH-inhibitory activity, and thus the present invention is completed. The urea compound or its pharmaceutically acceptable salt of the present invention can increase the effective bladder capacity and ameliorate the state of urinary frequency, and is therefore useful as an agent for treating urinary frequency, urinary incontinence and/or overactive bladder.